Kodiak Sciences Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 28, 2024. Although the request references Q4, this filing reports annual results, and the supplied text does not provide separate fourth-quarter financial figures. Kodiak is a clinical-stage retinal therapeutics company with no approved products and no product revenue.
Financial performance and position
| Metric | FY2023 / Dec. 31, 2023 | FY2022 / Dec. 31, 2022 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $206.3 million | $267.6 million |
| General and administrative expense | $71.0 million | $73.8 million |
| Operating loss | $277.3 million | $341.4 million |
| Net loss | $260.5 million; $4.97 per share | $333.8 million; $6.39 per share |
| Operating cash used | $154.2 million | $206.5 million |
| Cash and cash equivalents | $285.5 million | $190.4 million |
| Total assets / stockholders’ equity | $479.4 million / $265.8 million | $666.6 million / $436.2 million |
Gross margin is not applicable because Kodiak has no product sales. The company reported an accumulated deficit of $1.153 billion. It had $289.3 million of current assets and $41.7 million of current liabilities at year-end. Total liabilities were $213.6 million, including $100.0 million related to the sale of future royalties and operating lease liabilities; the filing does not identify material conventional borrowings.
Investing activities provided $249.2 million, primarily from net maturities of marketable securities, partly offset by $41.4 million of capital expenditures. Financing activities provided $31,000. FY2023 stock-based compensation was $88.6 million. Management estimated cash and cash equivalents would fund operations into 2026 and stated they should cover anticipated needs for at least 12 months after the filing date; both estimates depend on assumptions and may change.
Material developments and comparison
- Net loss narrowed by $73.3 million year over year, while operating expenses fell 19%. R&D expense declined 23%, mainly because tarcocimab pivotal studies were wound down; higher interest income, reflecting higher rates, also contributed to the lower net loss.
- Tarcocimab had mixed pivotal results: GLOW1 in diabetic retinopathy, BEACON in retinal vein occlusion, and DAYLIGHT in wet AMD met their primary endpoints. GLEAM and GLIMMER in diabetic macular edema and the earlier DAZZLE wet AMD study did not.
- After pausing tarcocimab development in 2023, Kodiak resumed it following positive results. GLOW2, a Phase 3 diabetic retinopathy study, was recruiting at the filing date. A tarcocimab arm in the planned DAYBREAK wet AMD study was targeted for mid-2024, subject to FDA alignment.
- In GLEAM/GLIMMER, tarcocimab did not meet non-inferiority endpoints; cataract adverse events were 19% with tarcocimab versus 9% with aflibercept in the pooled safety population. Kodiak believes cataract-related visual acuity decline contributed to the failures.
- KSI-501’s Phase 1 results were described by Kodiak as showing safety, tolerability, and bioactivity; the company planned a Phase 3 wet AMD study in 2024. KSI-101 was planned to enter Phase 1b in Q2 2024, with pivotal studies hoped to start later in 2024. These are forward-looking plans, not completed milestones in FY2023.
Liquidity, commitments, outlook, and risks
- Ursus, the Lonza-associated commercial-scale manufacturing suite, was commissioned as a cGMP facility in January 2023; Kodiak released its first commercial-scale cGMP tarcocimab batch in July and paid Lonza $26.8 million in October for final activation. The go-to-market tarcocimab drug product was released in March 2024, after year-end.
- Future undiscounted operating lease payments were $105.0 million, including $14.8 million due in 2024. Manufacturing obligations subject to potential cancellation fees were $15.4 million at year-end, including $11.0 million expected within 12 months. Additional potential Lonza manufacturing commitments were approximately CHF 123 million.
- A 2019 funding agreement provides Baker Bros. Advisors a capped 4.5% royalty on future global net sales of tarcocimab, terminating after cumulative payments of $450 million. The company had received $100 million; the remaining $125 million was canceled by amendment. Royalty payments were not considered probable and estimable at year-end.
- Kodiak expects continued losses and has no committed source of additional capital. Development delays, trial failures, manufacturing or formulation changes, reliance on Lonza and other third parties, competition, pricing and reimbursement, and patent risks could increase cash needs or delay commercialization. The company also disclosed risks from economic volatility, supply-chain disruption, and data-security and privacy requirements.
- No material legal proceedings were reported. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not provide an internal-control attestation because Kodiak was not required to obtain one. The financial statement audit opinion was unqualified.
Key facts for investors to verify
- Whether GLOW2 and the planned DAYBREAK studies meet their endpoints, and whether FDA agreement supports the intended combined regulatory strategy and bridging to the go-to-market formulation.
- Whether the cataract imbalance and visual-acuity shortfalls in GLEAM/GLIMMER affect tarcocimab’s safety profile, label prospects, or further development.
- Actual cash burn, financing needs, and runway as clinical programs advance; validate management’s “into 2026” estimate against future spending and trial costs.
- Whether Ursus is utilized as planned and whether Lonza commitments, supply availability, and manufacturing costs remain manageable.
- Whether KSI-501 and KSI-101 advance on schedule and reproduce the early results in larger trials; confirm the status of milestones planned after year-end.
- The assumptions supporting the no-impairment conclusion for $183.7 million of long-lived assets, a matter highlighted as a critical audit matter, and the potential effect of changes to tarcocimab development plans.
- How the capped royalty, lease obligations, equity compensation, and any future financing affect cash availability and shareholder dilution.